{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042251","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.494463+00:00","generated_at":"2026-05-21T16:47:14.642311+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing","bullets":["Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.","BayMedica revenue $1.26M (+8% YoY); gross margin declined due to pricing pressure.","Cash and equivalents $4.68M (Jun 30, 2024: $6.57M); expects to fund operations into Q3 2025.","R&D expenses $0.91M vs $0.65M YoY, driven by INM-901 and INM-089 programs.","Company seeks additional financing through equity, debt, or collaborations to fund pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042251","json":"https://secwatch.observer/filing/0001213900-25-042251.json","markdown":"https://secwatch.observer/filing/0001213900-25-042251.md","text":"https://secwatch.observer/filing/0001213900-25-042251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/0001213900-25-042251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025042251/ea0241856-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:47:14.642311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}